Across TCGA pan-cancer cohorts, C7orf57 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C7orf57 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher C7orf57 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C7orf57 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
READ, LUSC, and UCEC are the cancer types where C7orf57 Mutation most reproducibly stratifies survival.